NCT03107988 2025-09-15NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)New Approaches to Neuroblastoma Therapy ConsortiumPhase 1 Completed65 enrolled 38 charts
NCT04800822 2024-10-22PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1 Terminated53 enrolled
NCT03726333 2024-06-21Hepatic Impairment Study for Lorlatinib in Cancer PatientsPfizerPhase 1 Terminated1 enrolled 3 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled